Research across Cancer
Related studies from across the Cancer family.
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide Shows Promise for Prostate Cancer in HIV Patients
This is a single-patient case report describing rezvilutamide plus androgen deprivation therapy in an HIV-positive patient with high-volume …
A single patient with both HIV and advanced prostate cancer showed significant improvement after starting a specific combination of treatmen…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Integrated Prognostic Criteria Improve Survival Stratification in Metastatic Castration-Sensitive Prostate Cancer
Trial shows improved prediction of survival in prostate cancer
Combining CHAARTED and LATITUDE criteria enhances prognostic accuracy for mCSPC, though specific treatment benefits in certain subgroups rem…
A new way to combine two scoring systems helps doctors better predict how patients with advanced prostate cancer will respond to treatment.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer
Dose-boosting radiotherapy may improve survival for high-risk prostate cancer patients
This systematic review and meta-analysis evaluated hypofractionated and dose-boosted radiotherapy fractionation schedules versus standard ra…
Combining external beam radiotherapy with brachytherapy or a focal boost significantly improved metastasis-free survival in patients with cl…
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…